Instrumento Inactivo

Otros idiomas Stemline Therapeutics, Inc.

Acciones

US85858C1071

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium	11/12
Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023	08/12
The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU	20/11
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	30/10/23
European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation	20/09/23
The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study	25/05/23
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting	09/05/23
Stemline Therapeutics, Inc. Receives U.S. FDA Approval for ORSERDU	30/01/23
The Menarini Group and Stemline Therapeutics to Present Additional Data from the Phase 3 EMERALD Study of Elacestrant, an Investigational Oral SERD, During the Upcoming San Antonio Breast Cancer Symposium	30/11/22
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer	11/08/22
Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy	17/12/20
STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	10/06/20
Stemline Therapeutics, Inc. Announces Board Resignations	10/06/20
Stemline Therapeutics, Inc.(NasdaqCM:STML) dropped from S&P Global BMI Index	10/06/20
Stemline Therapeutics, Inc.(NasdaqCM:STML) dropped from S&P TMI Index	10/06/20
Stemline Therapeutics, Inc.(NasdaqCM:STML) dropped from S&P Biotechnology Select Industry Index	10/06/20
Berlin-Chemie AG completed the acquisition of Stemline Therapeutics, Inc..	10/06/20
STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	11/05/20
Stemline Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	11/05/20
Stemline Therapeutics : The Menarini Group signs the agreement for the acquisition of Stemline Therapeutics for a maximum consideration of $ 677 million	05/05/20

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Stemline Therapeutics, Inc.

Acciones

US85858C1071

Otros idiomas

Filtros